Combination of | |
---|---|
Daunorubicin | Anthracycline |
Cytarabine | Antimetabolite |
Clinical data | |
Trade names | Vyxeos |
Other names | CPX-351 |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
KEGG |
Daunorubicin/cytarabine is a fixed-dose combination medication used for the treatment of acute myeloid leukemia.[3][4] It contains the liposomal bound daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, a nucleoside metabolic inhibitor.[3]
Daunorubicin/cytarabine is indicated for the treatment of newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in people aged one year of age and older.[3][5][6][7][8]